The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

albuminuria chronic kidney disease cost-effectiveness creatinine cystatin detection glomerular filtration rate health systems interventions kidney failure proteinuria risk models risk stratification screening

Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
01 2021
Historique:
received: 15 07 2020
revised: 05 10 2020
accepted: 13 10 2020
pubmed: 1 11 2020
medline: 22 6 2021
entrez: 31 10 2020
Statut: ppublish

Résumé

Chronic kidney disease (CKD) causes substantial global morbidity and increases cardiovascular and all-cause mortality. Unlike other chronic diseases with established strategies for screening, there has been no consensus on whether health systems and governments should prioritize early identification and intervention for CKD. Guidelines on evaluating and managing early CKD are available but have not been universally adopted in the absence of incentives or quality measures for prioritizing CKD care. The burden of CKD falls disproportionately upon persons with lower socioeconomic status, who have a higher prevalence of CKD, limited access to treatment, and poorer outcomes. Therefore, identifying and treating CKD at the earliest stages is an equity imperative. In 2019, Kidney Disease: Improving Global Outcomes (KDIGO) held a controversies conference entitled "Early Identification and Intervention in CKD." Participants identified strategies for screening, risk stratification, and treatment for early CKD and the key health system and economic factors for implementing these processes. A consensus emerged that CKD screening coupled with risk stratification and treatment should be implemented immediately for high-risk persons and that this should ideally occur in primary or community care settings with tailoring to the local context.

Identifiants

pubmed: 33127436
pii: S0085-2538(20)31210-2
doi: 10.1016/j.kint.2020.10.012
pii:
doi:

Types de publication

Practice Guideline Research Support, Non-U.S. Gov't Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

34-47

Investigateurs

Georgi Abraham (G)
Zanfina Ademi (Z)
Radica Z Alicic (RZ)
Ian de Boer (I)
Raj Deo (R)
Xiaoqiang Ding (X)
Natalie Ebert (N)
Kevin J Fowler (KJ)
Linda F Fried (LF)
Ron T Gansevoort (RT)
Guillermo Garcia-Garcia (G)
Brenda R Hemmelgarn (BR)
Jessica Lee Harding (J)
Joanna Q Hudson (JQ)
Kunitoshi Iseki (K)
Vasantha Jotwani (V)
Leah S Karliner (LS)
Andrew S Levey (AS)
Adrian Liew (A)
Peter J Lin (PJ)
Andrea O Y Luk (AOY)
Verónica Martínez (V)
Andrew E Moran (AE)
Mai Nguyen (M)
Gregorio T Obrador (GT)
Donal O'Donoghue (D)
Meda E Pavkov (ME)
Jessie Pavlinac (J)
Neil R Powe (NR)
Jesse C Seegmiller (JC)
Jenny I Shen (JI)
Rukshana Shroff (R)
Laura Solá (L)
Maarten W Taal (MW)
James Tattersall (J)
Joseph A Vassalotti (JA)
Matthew R Weir (MR)
Ella Zomer (E)

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 Kidney Disease: Improving Global Outcomes (KDIGO). Published by Elsevier Inc. All rights reserved.

Auteurs

Michael G Shlipak (MG)

Kidney Health Research Collaborative, Department of Medicine, University of California San Francisco, San Francisco, California, USA; General Internal Medicine Division, Medical Service, San Francisco Veterans Affairs Health Care System, San Francisco, California, USA. Electronic address: michael.shlipak@ucsf.edu.

Sri Lekha Tummalapalli (SL)

Kidney Health Research Collaborative, Department of Medicine, University of California San Francisco, San Francisco, California, USA; General Internal Medicine Division, Medical Service, San Francisco Veterans Affairs Health Care System, San Francisco, California, USA.

L Ebony Boulware (LE)

Department of General Internal Medicine, Duke University School of Medicine, Durham, North Carolina, USA.

Morgan E Grams (ME)

Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.

Joachim H Ix (JH)

Division of Nephrology-Hypertension, Department of Medicine, University of California San Diego, San Diego, California, USA; Nephrology Section, Veterans Affairs San Diego Healthcare System, La Jolla, California, USA; Division of Preventive Medicine, Department of Family Medicine and Public Health, University of California San Diego, San Diego, California, USA.

Vivekanand Jha (V)

George Institute for Global Health, University of New South Wales, New Delhi, India; University of Oxford, Oxford, UK; Department of Nephrology, Manipal Academy of Higher Education, Manipal, India.

Andre-Pascal Kengne (AP)

Non-Communicable Diseases Research Unit, South African Medical Research Council, Cape Town, South Africa; Department of Medicine, University of Cape Town, Cape Town, South Africa.

Magdalena Madero (M)

Department of Medicine, Division of Nephrology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.

Borislava Mihaylova (B)

Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK; Institute of Population Health Sciences, Blizard Institute, Queen Mary University of London, London, UK.

Navdeep Tangri (N)

Department of Community Health Services, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.

Michael Cheung (M)

Kidney Disease: Improving Global Outcomes, Brussels, Belgium.

Michel Jadoul (M)

Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium.

Wolfgang C Winkelmayer (WC)

Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.

Sophia Zoungas (S)

Diabetes and Vascular Medicine Unit, Monash Health, Clayton, Victoria, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. Electronic address: sophia.zoungas@monash.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH